To cycle or not to cycle: a critical decision in cancer (original) (raw)
Norbury, C. & Nurse, P. Animal cell cycles and their control. Annu. Rev. Biochem.61, 441–470 (1992). CASPubMed Google Scholar
Hartwell, L. & Weinert, T. Checkpoints: controls that ensure the order of cell cycle events. Science246, 629–634 (1989). CASPubMed Google Scholar
Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol.13, 261–291 (1997). CASPubMed Google Scholar
Sherr, C. J. Cancer cell cycles revisited. Cancer Res.60, 3689–3695 (2000). CASPubMed Google Scholar
Meyerson, M. & Harlow, E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol.14, 2077–2086 (1994). CASPubMedPubMed Central Google Scholar
Jinno, S. et al. Oncogenic stimulation recruits cyclin-dependent kinase in the cell cycle start in rat fibroblast. Proc. Natl Acad. Sci. USA96, 13197–13202 (1999). CASPubMedPubMed Central Google Scholar
Rane, S. G. et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in B-cell hyperplasia. Nature Genet.22, 44–52 (1999). ArticleCASPubMed Google Scholar
Tsutsui, T. et al. Targeted disruption of Cdk4 delays cell cycle entry with enhanced p27Kip1 activity. Mol. Cell. Biol.19, 7011–7019 (1999).References7and8describe the generation of mice that are deficient for Cdk4. Cdk4 seems to be dispensable for the cell cycle in most cell types. Ablation of Cdk4, however, severely affects proliferation of specific cell types, such as pancreatic β-cells, which leads to diabetes. ArticleCASPubMedPubMed Central Google Scholar
Ye, X., Zhu, C. & Harper, W. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. Proc. Natl Acad. Sci. USA13, 1682–1686 (2001). Google Scholar
Nigg, E. A. Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Curr. Opin. Cell Biol.8, 312–317 (1996). CASPubMed Google Scholar
Ekholm, S. V. & Reed, S. I. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol.12, 676–684 (2000). CASPubMed Google Scholar
Malumbres, M. & Pellicer, A. Ras pathways to cell cycle control and cell transformation. Front. Biosci.3, D887–D912 (1998). CASPubMed Google Scholar
Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev.12, 3499–3511 (1998). CASPubMedPubMed Central Google Scholar
Alt, J. R., Cleveland, J. L., Hannink, M. & Diehl, J. A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev.14, 3102–3114 (2000). CASPubMedPubMed Central Google Scholar
Fantl, V., Stamp, G., Andrews, A., Rosewell, I. & Dickson, C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev.9, 2364–2372 (1995). CASPubMed Google Scholar
Sicinski, P. et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell82, 621–630 (1995). CASPubMed Google Scholar
Sherr, C. J. & Roberts, J. M. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev.13, 1501–1512 (1999). CASPubMed Google Scholar
Adams, P. D. Regulation of the retinoblastoma tumor suppressor protein by cyclin/CDKs. Biochim. Biophys. Acta1471, 123–133 (2001). Google Scholar
Harbour, J. W. & Dean, D. C. The pRb/E2F pathway: expanding roles and emerging paradigms. Genes Dev.14, 2393–2409 (2000). CASPubMed Google Scholar
Morris, E. J. & Dyson, N. J. Retinoblastoma protein partners. Adv. Cancer Res.82, 1–54 (2001). CASPubMed Google Scholar
Lundberg, A. S. & Weinberg, R. A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin–CDK complexes. Mol. Cell. Biol.18, 753–761 (1998). CASPubMedPubMed Central Google Scholar
Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A. & Dean, D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell98, 859–869 (1999). CASPubMed Google Scholar
Ezhevsky, S. A., Ho, A., Becker-Hapak, M., Davis, P. K. & Dowdy, S. F. Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo. Mol. Cell. Biol.21, 4773–4784 (2001).References21–23culminate a series of reports that describe the distinct effects of cyclin-d-dependent and cyclin-E-dependent CDKs on the RB protein. The different role of these kinases in RB regulation provides us with interesting insights regarding the regulation of the early G1 and late G1 phase. CASPubMedPubMed Central Google Scholar
Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. & La Thangue, N. B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nature Cell Biol.3, 667–674 (2001). CASPubMed Google Scholar
Tamrakar, S., Rubin, E. & Ludlow, J. W. Role of pRb dephosphorylation in cell cycle regulation. Front. Biosci.5, D121–D137 (2000). CASPubMed Google Scholar
Van den Heuvel, M. & Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science262, 2050–2054 (1993).This study provided evidence for a distinct role of the different CDKs in G1/S progression. Whereas dominant-negative forms of CDK2 or CDK3 can arrest cultured cells in G1, similar mutant forms of CDK4 or CDK6 cannot. CASPubMed Google Scholar
Zhang, H. S., Postigo, A. A. & Dean, D. C. Active transcriptional repression by the Rb–E2F complex mediates G1 arrest triggered by p16INK4a, TGFβ, and contact inhibition. Cell97, 53–61 (1999). CASPubMed Google Scholar
Blain, S. W., Montalvo, E. & Massagué, J. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin-A–Cdk2 and cyclin-D2–Cdk4. J. Biol. Chem.272, 25863–25872 (1997). CASPubMed Google Scholar
LaBaer, J. et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev.11, 847–862 (1997). CASPubMed Google Scholar
Cheng, M. et al. The p21Cip1 and p27Kip1 Cdk inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J.18, 1571–1583 (1999).References28–30illustrate the differential consequences of the binding of WAF1/KIP inhibitors to CDK4/6–cyclin-D and CDK2–cyclin-E/A complexes. CASPubMedPubMed Central Google Scholar
Geng, Y. et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell97, 767–777 (1999).Replacement of cyclin D1 by a human cyclin E1 cDNA restores most of the deficiencies of cyclin-D1 knockout mice. As cyclin E cannot activate CDK4 or CDK6, these observations indicate that cyclin E1 is a main downstream target of cyclin D1. CASPubMed Google Scholar
Geng, Y. et al. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc. Natl Acad. Sci. USA, 98, 194–199 (2001). CASPubMed Google Scholar
Tong, W. & Pollard, J. W. Genetic evidence for the interactions of cyclin D1 and p27Kip1 in mice. Mol. Cell. Biol.21, 1319–1328 (2001). CASPubMedPubMed Central Google Scholar
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M. & Clurman, B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev.11, 1464–1478 (1997). CASPubMed Google Scholar
Malek, N. P. et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature413, 323–327 (2001).Cells that express a knock-inKip1T187A mutant are unable to downregulate Kip1 during S and G2. However, this mutation does not affect Kip1 downregulation in G1, indicating the existence of an alternative degradation process. CASPubMed Google Scholar
Moberg, K. H., Bell, D. W., Wahrer, D. C. R., Haber, D. A. & Hariharan, I. K. Archipielago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature413, 311–316 (2001). CASPubMed Google Scholar
Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature413, 316–322 (2001). CASPubMed Google Scholar
Koepp, D. M. et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science294, 173–177 (2001). CASPubMed Google Scholar
Wolfel, T. et al. A p16Ink4a-insensitive Cdk4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science269, 1281–1284 (1995).First description of a tumour-associated point mutation in a CDK molecule. Interestingly, this CDK4 mutation (R24C) disrupts the binding with the INK4 family of inhibitors, highlighting the importance of this interaction in tumour development. CASPubMed Google Scholar
Easton, J., Wei, T., Lahti, J. M. & Kidd, V. J. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res.58, 2624–2632 (1998). CASPubMed Google Scholar
Latres, E. et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl Acad. Sci. USA98, 2515–2520 (2001). CASPubMedPubMed Central Google Scholar
Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA98, 5043–5048 (2001). CASPubMedPubMed Central Google Scholar
Wu, C.-L. et al. Cables enhances Cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res.61, 7325–7332 (2001). CASPubMed Google Scholar
Paggi, M. G. & Giordano, A. Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother. Cancer Res.61, 4651–4654 (2001). CASPubMed Google Scholar
Lee, E. Y. H. P. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. Nature359, 288–294 (1992). CASPubMed Google Scholar
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature359, 295–300 (1992). CASPubMed Google Scholar
Mulligan, G. & Jacks, T. The retinoblastoma gene family: cousins with overlapping interests. Trends Genet.14, 223–229 (1998). CASPubMed Google Scholar
Robanus-Maandag, E. et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev.12, 1599–1609 (1998). CASPubMedPubMed Central Google Scholar
Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell85, 733–744 (1996). CASPubMed Google Scholar
Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell85, 721–732 (1996). CASPubMed Google Scholar
Nakayama, K. et al. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell85, 707–720 (1996). CASPubMed Google Scholar
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M. & Kemp, C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature396, 177–180 (1998). CASPubMedPubMed Central Google Scholar
Martin-Caballero, J., Flores, J. M., Garcia-Palencia, P. & Serrano, M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res.61, 6234–6238 (2001). CASPubMed Google Scholar
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A. & Berns, A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature413, 83–86 (2001). CASPubMed Google Scholar
Sharpless, N. E. et al. Loss of p16INK4a with retention of p19ARF predisposes to tumorigenesis. Nature413, 86–91 (2001).References54and55define the specific role of INK4A as a tumour suppressor. They also highlight that loss of INK4A increases predisposition for melanoma, a neoplasia in which theCDKN2A(which encodes INK4A and ARF) region was first described as a susceptibility locus (see also reference59). CASPubMed Google Scholar
Latres, E. et al. Limited overlapping roles of p15_INK4b_ and p18_INK4c_ cell cycle inhibitors in proliferation and tumorigenesis. EMBO J.19, 3496–3506 (2000). CASPubMedPubMed Central Google Scholar
Franklin, D. S. et al. Cdk inhibitors p18Ink4c and p27Kip1 mediate two separate pathways to collaborative suppress pituitary tumorigenesis. Genes Dev.12, 2899–2911 (1998). CASPubMedPubMed Central Google Scholar
Sotillo, R. et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. (in the press).
Wang, T. C. et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature369, 669–671 (1994).These studies (references58–60) illustrate the role of CDK4–cyclin-D misregulation in tumour development and tumour susceptibility. CASPubMed Google Scholar
Bortner, D. M. & Rosenberg, M. P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol.17, 453–459 (1997). CASPubMedPubMed Central Google Scholar
Brugarolas, J., Bronson, R. T. & Jacks, T. p21 is a critical regulator essential for proliferation control in Rb-deficient cells. J. Cell Biol.141, 503–514 (1998). CASPubMedPubMed Central Google Scholar
Park, M. S. et al. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc. Natl Acad. Sci. USA96, 6382–6387 (1999). CASPubMedPubMed Central Google Scholar
Franklin, D. S., Godfrey, V. L., O'Brien, D. A., Deng, C. & Xiong, Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol.20, 6147–6158 (2000). CASPubMedPubMed Central Google Scholar
Chen, Y.-N. P. et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl Acad. Sci. USA96, 4325–4329 (1999). CASPubMedPubMed Central Google Scholar
Blagosklonny, M. V. & Pardee, A. B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res.61, 4301–4305 (2001). CASPubMed Google Scholar
Noble, M. E. M. & Endicott, J. A. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther.82, 269–278 (1999). CASPubMed Google Scholar
Sandig, V. et al. Adenovirally transferred p16INK4a/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med.3, 313–319 (1997). CASPubMed Google Scholar
Fahraeus, R., Lain, S., Ball, K. L. & Lane, D. P. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene16, 587–596 (1998). CASPubMed Google Scholar
Lubbert, M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol.249, 135–164 (2000). CASPubMed Google Scholar
Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res.59, 2615–2622 (1999). CASPubMed Google Scholar
Arber, N. et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res.57, 1569–1574 (1997). CASPubMed Google Scholar
Pestell, K. E., Ducruet, A. P., Wipf, P. & Lazo, J. S. Small molecule inhibitors of dual specificity protein phosphatases. Oncogene19, 6607–6612 (2000). CASPubMed Google Scholar
Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators and Cip and Ink inhibitors. J. Mol. Biol.287, 821–828 (1999). CASPubMed Google Scholar
Gray, N. S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science281, 533–538 (1998).An example of the synergistic combination ofin vitroandin silicoapproaches in the search for CDK inhibitors of therapeutic value. CASPubMed Google Scholar
Lander et al. Initial sequencing and analysis of the human genome. Nature409, 860–921 (2001). CASPubMed Google Scholar
Garrett, M. D. & Fattaey, A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev.9, 104–111 (1999). CASPubMed Google Scholar
Crews, C. M. & Mohan, R. Small-molecule inhibitors of the cell cycle. Curr. Opin. Chem. Biol.4, 47–53 (2000). CASPubMed Google Scholar
Hoessel, R. et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol.1, 60–67 (1999).Indirubin can specifically inhibit CDKs and arrest cell-cycle progression. An example of how classical Chinese medicine might help to identify inhibitors of molecular targets. CASPubMed Google Scholar
Senderowicz, A. M. & Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl Cancer Inst.92, 376–387 (2000). CASPubMed Google Scholar
Brooks, G. & La Thangue, N. B. The cell cycle and drug discovery: the promise and the hope. Drug Discovery Today4, 455–464 (1999). CASPubMed Google Scholar
Meijer, L., Leclerc, S. & Leost, M. Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther.82, 279–284 (1999). CASPubMed Google Scholar
Wood, K. W., Cornwell, W. D. & Jackson, J. R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol.1, 370–377 (2001). CASPubMed Google Scholar
Altmann, K.-H. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr. Opin. Chem. Biol.5, 424–431 (2001). CASPubMed Google Scholar
Thomas, G. An encore for ribosome biogenesis in the control of cell proliferation. Nature Cell. Biol.2, E71–E72 (2000). CASPubMed Google Scholar
Schmelzle, T. & Hall, M. N. TOR, a central controller of cell growth. Cell103, 253–262 (2000). CASPubMed Google Scholar
Rohde, J., Heitman, J. & Cardenas, M. E. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem.276, 9583–9586 (2001). CASPubMed Google Scholar
Fukunaga, R. & Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J.16, 1921–1933 (1997). CASPubMedPubMed Central Google Scholar
Waskiewicz, A. J., Flynn, A., Proud, C. G. & Cooper, J. A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J.16, 1909–1920 (1997). CASPubMedPubMed Central Google Scholar
Pardee, A. B. A restriction point for control of normal animal cell proliferation. Proc. Natl Acad. Sci. USA71, 1286–1290 (1974). CASPubMedPubMed Central Google Scholar
Planas-Silva, M. D. & Weinberg, R. A. The restriction point and control of cell proliferation. Curr. Opin. Cell Biol.9, 768–772 (1997). CASPubMed Google Scholar
Dannenberg, J.-H., van Rossum, A., Schuijff, L. & te Riele, H. Ablation of the retinoblastoma gene family deregulates G1 control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev.14, 3051–3064 (2000). CASPubMedPubMed Central Google Scholar
Sage, J. et al. Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. Genes Dev.14, 3037–3050 (2000).References92and93illustrate the specific and redundant roles of the RB protein family members in regulating the cell cycle. CASPubMedPubMed Central Google Scholar
Park, M. & Krause, M. W. Regulation of postembryonic G1 cell cycle progression in Caenorhabditis elegans by a cyclin D/CDK-like complex. Development126, 4849–4860 (1999). CASPubMed Google Scholar
Meyer, C. A. et al. Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression. EMBO J.19, 4533–4542 (2000).Shows that inDrosophila, the single cyclin-d-dependent Cdk (equivalent to mammalian CDK4 and CDK6) is not required for cell proliferation but affects homeotic cell number. CASPubMedPubMed Central Google Scholar
Datar, S. A., Jacobs, H. W., de la Cruz, A. F., Lehner, C. F. & Edgar, B. A. The Drosophila cyclin-D–Cdk4 complex promotes cellular growth. EMBO J.19, 4543–4554 (2000). CASPubMedPubMed Central Google Scholar
Yu, Q., Geng, Y. & Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature411, 1017–1021 (2001).Genetic analysis of the relationship between the tumorigenic properties of specific oncogenes and cyclin D1 in breast cancer. This report exemplifies the use of genetic models to shape specific pathways for therapeutic intervention in human cancer. CASPubMed Google Scholar
Shah, J. V. & Cleveland, D. W. Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell103, 997–1000 (2000). CASPubMed Google Scholar
Nigg, E. A. Cell division mitotic kinases as regulators of cell division and its checkpoints. Nature Rev. Mol. Cell. Biol.2, 21–32 (2001). CAS Google Scholar
Cahill, D. P. et al. Mutations of mitotic checkpoint genes in human cancers. Nature392, 300–303 (1998). CASPubMed Google Scholar
Michel, L. S. et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature409, 355–359 (2001).First genetic demonstration that defects in the mitotic checkpoint can lead to tumour development. CASPubMed Google Scholar
Hernando, E. et al. Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int. J. Cancer95, 223–227 (2001). CASPubMed Google Scholar
Smith, M. R. et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun.234, 397–405 (1997). CASPubMed Google Scholar
Simizu, S. & Osada, H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nature Cell. Biol.2, 852–854 (2000). CASPubMed Google Scholar
Giet, R. & Prigent, C. Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J. Cell. Sci.112, 3591–3601 (1999). CASPubMed Google Scholar
Zou, H., McGarry, T. J., Bernal, T. & Kirschner, M. W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science285, 418–422 (1999). CASPubMed Google Scholar
Tao, W. et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nature Genet.21, 177–181 (1999). CASPubMed Google Scholar
St John, M. A. R. et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nature Genet.21, 182–186 (1999).References107and108provide the first link between CDK1 deregulation and tumour development. These reports raise important questions regarding a possible role of CDK1 in cell transformation. CASPubMed Google Scholar
Vesely, J. et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem.224, 771–786 (1994). CASPubMed Google Scholar
De Azevedo, W. F., Leclerc, S., Meijer, L., Strand, M. & Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem.243, 518–526 (1997). CASPubMed Google Scholar
Arris, C. E. et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem.43, 2797–2804 (2000). CASPubMed Google Scholar
Zaharevitz, D. W. et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res.59, 2566–2569 (1999). CASPubMed Google Scholar
Kitagawa et al. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene9, 2549–2557 (1994). CASPubMed Google Scholar
Meijer, L. et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol.7, 51–63 (1999). Google Scholar
Lane, M. E. et al. A novel cdk2-inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res.61, 6170–6177 (2001). CASPubMed Google Scholar
Soni, R. et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl Cancer Inst.93, 436–446 (2001). CASPubMed Google Scholar
Fry, D. W. et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem.276, 16617–16623 (2001). CASPubMed Google Scholar
Soni, R. et al. Inhibition of cyclin–dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun.275, 877–884 (2000). CASPubMed Google Scholar